Capsule polysaccharide is a bacterial decoy for antimicrobial peptides.
Antimicrobial peptides (APs) are important host weapons against infections. Nearly all APs are cationic and their microbicidal action is initiated through interactions with the anionic bacterial surface. It is known that pathogens have developed countermeasures to resist these agents by reducing the negative charge of membranes, by active efflux and by proteolytic degradation. Here we uncover a new strategy of resistance based on the neutralization of the bactericidal activity of APs by anionic bacterial capsule polysaccharide (CPS). Purified CPSs from Klebsiella pneumoniae K2, Streptococcus pneumoniae serotype 3 and Pseudomonas aeruginosa increased the resistance to polymyxin B of an unencapsulated K. pneumoniae mutant. Furthermore, these CPSs increased the MICs of polymyxin B and human neutrophil alpha-defensin 1 (HNP-1) for unencapsulated K. pneumoniae, Escherichia coli and P. aeruginosa PAO1. Polymyxin B or HNP-1 released CPS from capsulated K. pneumoniae, S. pneumoniae serotype 3 and P. aeruginosa overexpressing CPS. Moreover, this material also reduced the bactericidal activity of APs. We postulate that APs may trigger in vivo the release of CPS, which in turn will protect bacteria against APs. We found that anionic CPSs, but not cationic or uncharged ones, blocked the bactericidal activity of APs by binding them, thereby reducing the amount of peptides reaching the bacterial surface. Supporting this, polycations inhibited such interaction and the bactericidal activity was restored. We postulate that trapping of APs by anionic CPSs is an additional selective virulence trait of these molecules, which could be considered as bacterial decoys for APs.
Llobet
Enrique
E
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola, Spain.|Program Infection and Immunity, Fundació Caubet-CIMERA Illes Balears, Bunyola, Spain.
Tomás
Juan M
JM
Departamento de Microbiología, Facultad de Biología, Universidad de Barcelona, Barcelona, Spain.
Bengoechea
Jose A
JA
Área de Microbiología, Facultad Biología, Universitat Illes Balears, Palma Mallorca, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola, Spain.|Program Infection and Immunity, Fundació Caubet-CIMERA Illes Balears, Bunyola, Spain.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D023181:Antimicrobial Cationic Peptides / Q000378:metabolism* / Q000494:pharmacology*; D016667:Bacterial Capsules / Q000378:metabolism*; D024881:Drug Resistance, Bacterial; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000472:pathogenicity; D008826:Microbial Sensitivity Tests / Q000379:methods; D011112:Polymyxin B / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000472:pathogenicity; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000472:pathogenicity
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D011112:Polymyxin B